Current guidelines for the treatment of CLL indicate that the second generation BTK inhibitor, acalabrutinib (approved for the treatment of CLL), and the next generation BTK inhibitor, zanubrutinib (not approved for CLL), are both among the preferred 1L treatment options in addition to ibrutinib [32]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.